



BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day

October 8, 2026 11:00 AM IDT

TEL AVIV, Israel and OSLO, Norway, Oct. 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day, taking place November 12-15 in Philadelphia, Pennsylvania.



The presentations will highlight preclinical research evaluating GLIX1 across multiple glioblastoma models, as well as the design of the ongoing Phase 1/2a clinical trial evaluating GLIX1 in patients with recurrent or progressive high-grade glioma and other solid tumors.

Presentation Details:

Title: GLIX1, a TET2 activator targeting DNA damage response: potent anti-tumor activity across multiple glioblastoma models; orthotopic CDX models and a subcutaneous TMZ-resistant PDX model

Presenter: Dr. Adam Robertson, Ph.D., Chief Scientific Officer, Hemispherian AS

Abstract code: EXTH-31

Format: Poster presentation

Date/time: Friday, November 13, 2026, 7:30-9:30 p.m. EST

Location: Pennsylvania Convention Center, Exhibit Halls D and E

Title: Phase 1/2a study of GLIX1, a novel first-in-class oral TET2 activator, for the treatment of recurrent or progressive high-grade glioma

Presenter: Ditte Primdahl, MD, Northwestern University Feinberg School of Medicine

Abstract code: CTNI-25

Format: Poster presentation

Date/time: Friday, November 13, 2026, 7:30-9:30 p.m. EST

Location: Pennsylvania Convention Center, Exhibit Halls D and E

About the Society for Neuro-Oncology (SNO)

The Society for Neuro-Oncology (SNO) Annual Meeting brings together researchers and clinicians to share advances in brain tumor research and treatment. For more information, please visit: <https://www.soc-neuro-onc.org/meetings-education/31st-society-for-neuro-oncology-annual-meeting-education-day>.

About Hemispherian

Hemispherian AS is a clinical-stage pharmaceutical company developing first-in-class small-molecule cancer therapies. Its lead program, GLIX1, is being advanced in partnership with BioLineRx for the treatment of glioblastoma and a broad range of solid tumors.

The company is headquartered in Oslo, Norway, and collaborates with leading academic and clinical institutions worldwide.

Learn more at www.hemispherian.com or on [LinkedIn](#).

About BioLineRx

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial was initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.

The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

Learn more about who we are, what we do, and how we do it at www.bioglinerx.com, or on [LinkedIn](#).

Forward Looking Statement

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the expectations with regard to BioLineRx's Phase 1/2a GLIX1 clinical trial and BioLineRx's business strategy. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of GLIX1 and motixafortide including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance GLIX1 and motixafortide into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results for GLIX1 and motixafortide will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for GLIX1 and motixafortide and the timing of other regulatory filings and approvals; whether access to GLIX1 and motixafortide is achieved in a commercially viable manner and whether GLIX1 and motixafortide receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel, as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection that BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its need for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; statements as to the impact of the political and security situation in Israel on BioLineRx's business which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2026. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg

Logo: <https://mma.prnewswire.com/media/2966446/Hemispherian.jpg>

Contacts:

For BioLineRx:

United States:
Chuck Padala
LifeSci Advisors, LLC
ir@bioglinerx.com

Israel:
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

For Hemispherian AS:

Zeno Albisser, CEO
zeno@hemispherian.com

 View original content: <https://www.prnewswire.com/news-releases/bioglinerx-and-hemispherian-announce-two-glix1-presentations-at-the-31st-society-for-neuro-oncology-sno-annual-meeting--education-day-302902311.html>

SOURCE BioLineRx Ltd.; Hemispherian AS

+972-8-6429100